-
Product Insights
Malignant Neoplasms - Drugs In Development, 2024
Empower your strategies with our Malignant Neoplasms – Drugs In Development, 2024 report and make more profitable business decisions. A tumor is a mass comprising atypical neoplastic cells, frequently exhibiting pleomorphism and the capability to invade surrounding tissues. Malignant neoplasms possess the characteristic of metastasizing to distant anatomical sites and may recur even after surgical excision. Among the most prevalent types of malignant neoplasms are carcinomas, which arise from epithelial tissues, Hodgkin and non-Hodgkin lymphomas originating in the lymphatic system, leukemias...
-
Product Insights
Oligodendroglioma - Drugs In Development, 2024
Empower your strategies with our Oligodendroglioma – Drugs In Development, 2024 report and make more profitable business decisions. Oligodendroglioma is a type of glioma (primary glial brain tumor). They often contain mineral deposits (called calcifications), areas of hemorrhage, and/or cysts. The most common symptoms are seizures, headaches, and personality changes. Other symptoms vary by location and size of the tumor. Treatment includes chemotherapy surgery and radiation therapy. The Oligodendroglioma drugs in development market research report provide comprehensive information on the therapeutics...
-
Product Insights
Papillary Renal Cell Carcinoma - Drugs In Development, 2024
Empower your strategies with our Papillary Renal Cell Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Papillary renal cell carcinoma (PRCC), a form of kidney cancer, originates in the tubes responsible for filtering waste from the blood. There are two subtypes: Type 1, more common and slow-growing, and type 2, aggressive and fast-growing. Symptoms may include blood in urine, pain, weight loss, fatigue, fever, or a palpable lump. Diagnosis involves imaging scans like CT, MRI, and...
-
Product Insights
Germ Cell Tumors - Drugs In Development, 2024
Empower your strategies with our Germ Cell Tumors – Drugs In Development, 2024 report and make more profitable business decisions. Germ cell tumors (GCTs), originating from primordial germ cells, exhibit diverse neoplasms primarily in gonads but also in the anterior mediastinum, pineal gland, and brain. Clinical classification distinguishes seminomas and non-seminomas, each with distinct prognoses. Seminomas typically show favorable outcomes, while non-seminomatous tumors may present with metastasis, including mixed germ cell components. Diagnosing germinoma involves imaging, serum/cerebrospinal fluid oncoprotein measurements, and...
-
Product Insights
Polycythemia Vera - Drugs In Development, 2024
Empower your strategies with our Polycythemia Vera – Drugs In Development, 2024 report and make more profitable business decisions. Polycythemia vera (PV) is a stem cell disorder characterized as a panhyperplastic, malignant, and neoplastic marrow disorder. Symptoms include itchiness, headache, dizziness, weakness, and excessive sweating. The risk of PV increases with age. Treatment includes alkylating agents. The Polycythemia Vera drugs in development market research report provide comprehensive information on the therapeutics under development for Polycythemia Vera, complete with analysis by stage...
-
Product Insights
Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) - Drugs In Development, 2024
Empower your strategies with our Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) – Drugs In Development, 2024 report and make more profitable business decisions. Primary myelofibrosis (PMF) is a rare bone marrow disorder marked by irregularities in blood cell production and the development of fibrous tissue within the bone marrow. Hematopoietic stem cells in the bone marrow, responsible for generating red blood cells, white blood cells, and platelets, undergo DNA changes in PMF, leading to continuous abnormal cell reproduction. Over time, these aberrant...
-
Product Insights
Follicular Thyroid Cancer - Drugs In Development, 2024
Empower your strategies with our Follicular Thyroid Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Follicular thyroid carcinoma is a cancer that forms in follicular cells of the thyroid. Follicular thyroid cancer constitutes 10 to 15% of all thyroid cancer cases, making it the second most common. Unlike differentiated types, undifferentiated types are rare. Diagnosis of follicular thyroid carcinoma relies on pathologic confirmation of follicular cells devoid of the nuclear atypia seen in papillary thyroid cancer,...
-
Product Insights
Lymphoproliferative Disorders - Drugs In Development, 2024
Empower your strategies with our Lymphoproliferative Disorders – Drugs In Development, 2024 report and make more profitable business decisions. Lymphoproliferative disorders (LPD) constitute a diverse group of diseases marked by uncontrolled lymphocyte production, resulting in monoclonal lymphocytosis, lymphadenopathy, and bone marrow infiltration. Predominantly affecting immunocompromised individuals, these disorders involve two subsets of lymphocytes, T and B cells, leading to immunoproliferative disorders with inherent risks of immunodeficiency and lymphocyte dysregulation. Causative gene mutations, whether iatrogenic or acquired, are identified through somatic or...
-
Product Insights
Essential Thrombocythemia - Drugs In Development, 2024
Empower your strategies with our Essential Thrombocythemia – Drugs In Development, 2024 report and make more profitable business decisions. Essential thrombocythemia is a chronic myeloproliferative neoplasm in which cells in the bone marrow that produce the blood cells develop and function abnormally. In essential thrombocythemia, there is mainly an overproduction of platelet-forming cells (megakaryocytes) in the marrow. Symptoms of essential thrombocythemia include headache, dizziness, weakness or numbness on one side of the body, slurred speech, and transient ischemic attacks. The Essential...
-
Product Insights
Small Intestine Cancer - Drugs In Development, 2024
Empower your strategies with our Small Intestine Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Small intestine cancer, a rare malignancy, originates when malignant cells form in the tissues of the small intestine. This vital organ, composed of diverse cell types, gives rise to various cancer types. Adenocarcinomas, arising from gland cells lining the intestine, constitute approximately one-third of small intestine cancers. Carcinoid tumors, a subtype of neuroendocrine tumors, are generally slow-growing and the most prevalent...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.